Business
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program
Watch the "What This Means" video here Featuring Company’s second-generation T-Cell Engager program and advantages over first-generation Company’s T-Cell Engager program has made improvements in manufacturability, preclinical safety profile, and ability to treat a wide spectrum of solid tumors MIRAMAR, Fla., Sept. 30, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and dev
About this update from Hcw Biologics Inc.
[{"type":"image","alt":"HCW Biologics Inc.","displaySize":"","headline":null,"caption":"HCW Biologics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/41c465fea041fccd686f09c17f724fb7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8op9ybYTjyQdFXiaAcCiSw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/41c465fea041fccd686f09c17f724fb7","width":300,"height":150}},"lazy":false},{"type":"text","content":"Watch the "What This Means" video here","length":48,"tagName":"p"},{"type":"text","content":"Featuring Company’s second-generation T-Cell Engager program and advantages over first-generation","length":103,"tagName":"p"},{"type":"text","content":"Company’s T-Cell Engager program has made improvements in manufacturability, preclinical safety profile, and ability to treat a wide spectrum of solid tumors","length":157,"tagName":"p"},{"type":"text","content":"MIRAMAR, Fla., Sept. 30, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today announced that Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations of HCW Biologics, participated in a Virtual Investor “What This Means” segment.","length":513,"tagName":"p"},{"type":"text","content":"As part of the segment, Dr. Rhode discussed the Company’s recent news announcing its TRBC-based second-generation T-Cell Engager (“TCE”) program and the positive safety profile from a non-human primate investigative study recently conducted by the Company for its TCE program. HCW Biologics believes its second-generation TCEs could alleviate the challenges of the first generation TCEs, such as complex manufacturing processes, tolerability, safety, antigen selection, and efficacy for solid tumors. The Company has joined a small group of innovative biotechnology companies who have discovered new TCEs that overcome resistance mechanisms and improve the ability to treat solid tumors.","length":692,"tagName":"p"},{"type":"text","content":"The Virtual Investor “What This Means” segment feat...